Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
Nicoletta FerrariIlaria GranataMatteo CapaiaMarina PiccirilloMario Rosario GuarracinoRoberta VenèAntonella BrizzolaraAndrea PetrettoElvira IngleseMartina MoriniSimonetta AstigianoAdriana Agnese AmaroFrancesco BoccardoCecilia BalbiPaola BarboroPublished in: Cell communication and signaling : CCS (2017)
Our models suggest that environmental factors and epigenetic modulation can activate processes of phenotypic adaptation driving drug-resistance. The identified key proteins of these adaptive phenotypes could be eligible targets for innovative therapies as well as molecules of prognostic and predictive value.